Study CC-92328-MM-001 is a multicenter, open-label, two-part, first-in-human (FIH), Phase 1, dose finding study to determine the safety, tolerability, PK, and pharmacodynamics (PD) of CC-92328 in subjects with R/R MM. The study will start with a dose escalation phase (Part A), guided by a hybrid of a modified accelerated titration design and the two-parameter Bayesian logistic regression model (BLRM), to determine the MTD, and/or RP2D of CC-92328.
To determine the safety and tolerability of CC-92328 in subjects with R/R MM. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-92328 in subjects with R/R MM.
OPEN TO ACCRUAL